T cell vaccination benefits relapsing progressive multiple sclerosis patients: a randomized, double-blind clinical trial.

Background: T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled.

Aim: To evaluate the safety and efficacy of TCV in progressive MS, in a double-blind, controlled clinical trial.

Optimal timing of joint replacement using mathematical programming and stochastic programming models.

The optimal timing for performing radical medical procedures as joint (e.g., hip) replacement must be seriously considered.